Stockscreener 앱 받기
8.94
1.22%
-0.11
시간 외 거래:
8.94
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit - The Manila Times
Obesity drug from Corbus shows rapid weight loss in early trial - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Prosight Management LP Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through - openPR.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat
Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf registration - Stock Titan
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance
Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Corbus Pharmaceuticals (CRBP) to $57 | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. 2024 Annual Report: Pipeline, Intellectual Property, Regulatory Overview, and Business Strategy - Minichart
Corbus Pharmaceuticals (CRBP) Beats Q4 EPS Estimates - GuruFocus
Corbus Pharmaceuticals (NASDAQ: CRBP) details 2025 losses, cash and key trial data - Stock Titan
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results, Highlights Promising CRB-701 and CRB-913 Clinical Updates and Extends Cash Runway Into 2028 - Minichart
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines - Traders Union
Corbus Pharmaceuticals 2025 Financials: Q4 Loss of $20.6M, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress - TipRanks
Corbus Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results - MarketBeat
Corbus Pharmaceuticals (CRBP) Eyes Breakthroughs with CRB-701 an - GuruFocus
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - Bitget
CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings - Quiver Quantitative
Corbus Pharmaceuticals: Q4 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
CRBP: Strong clinical progress and financing position support continued development into 2028 - TradingView
Corbus Pharmaceuticals (NASDAQ: CRBP) widens 2025 loss but boosts cash and pipeline progress - Stock Titan
Income Plays: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveMarket Movement Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Buyout Rumor: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesJuly 2025 Action & Real-Time Sentiment Analysis - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus (NASDAQ: CRBP) CMO offloads shares in tax-related RSU sale - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday - MarketBeat
Insider sale notice — CRBP (NASDAQ: CRBP) lists 12,500 RSUs - Stock Titan
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Aug Movers: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rateJuly 2025 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
Fund Flows: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rate2025 Buyback Activity & Fast Momentum Stock Entry Tips - baoquankhu1.vn
CRBP Should I Buy - Intellectia AI
Corbus Pharmaceuticals Holdings, Inc. advances CRB-701 for Nectin-4 solid tumors in early-stage development - Traders Union
Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead - MarketBeat
Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook - The Globe and Mail
EDGAR Filing Documents for 0001193125-26-068566 - SEC.gov
Corbus updates corporate presentation, details 2026 clinical and financial milestones - TradingView
Corbus Pharmaceuticals (CRBP) highlights oncology and obesity pipeline progress - Stock Titan
CRBPCorbus Pharmaceu Latest Stock News & Market Updates - Stock Titan
CRBP News Today | Why did Corbus Pharmaceuticals stock go up today? - MarketBeat
Chart Watch: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesProduct Launch & Safe Swing Trade Setups - baoquankhu1.vn
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Jefferies Financial Group - Defense World
1.20%
0.06%
자본화:
|
볼륨(24시간):